Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026)

Savara's (SVRA) quarterly Net Income towards Common Stockholders came in at -$37.3 million in Q1 2026, down 39.96% year-on-year from -$62.1 million in Q1 2025, and down 15.66% on a QoQ basis from -$32.2 million in Q4 2025.

Savara (SVRA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Savara (SVRA) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$37.3 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 39.96% year-over-year to -$37.3 million in Q1 2026; TTM through Mar 2026 was -$129.5 million, a 26.73% decrease from a year earlier, with the FY2025 full-year figure at -$118.8 million, down 23.94% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$37.3 million, down from -$32.2 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for SVRA reached as high as -$8.3 million in Q1 2022 and fell as low as -$37.3 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$20.3 million across 5 years, with a median of -$20.3 million in 2024.
  • Across the five-year window, Net Income towards Common Stockholders rose 18.76% in 2022 and tumbled 94.38% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$10.3 million in 2022, then tumbled by 56.3% to -$16.1 million in 2023, then slumped by 80.41% to -$29.0 million in 2024, then declined by 10.99% to -$32.2 million in 2025, then dropped by 15.66% to -$37.3 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$37.3 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Savara 1.39 Bn 1.39 Bn - -37.28 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -37.28 Mn
Dec 31, 2025 -32.24 Mn
Sep 30, 2025 -29.56 Mn
Jun 30, 2025 -30.40 Mn
Mar 31, 2025 -26.64 Mn
Dec 31, 2024 -29.04 Mn
Sep 30, 2024 -24.25 Mn
Jun 30, 2024 -22.24 Mn
Mar 31, 2024 -20.35 Mn
Dec 31, 2023 -16.10 Mn
Sep 30, 2023 -16.60 Mn
Jun 30, 2023 -11.44 Mn
Mar 31, 2023 -10.56 Mn
Dec 31, 2022 -10.30 Mn
Sep 30, 2022 -10.39 Mn
Jun 30, 2022 -9.16 Mn
Mar 31, 2022 -8.30 Mn
Dec 31, 2021 -11.31 Mn
Sep 30, 2021 -10.55 Mn
Jun 30, 2021 -10.94 Mn